Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the company's 13 ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Pfizer just pulled the plug on its daily weight-loss pill, danuglipron, after a clinical trial flagged a potential ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: Trump’s tariff regime is open to compromises.